跳至主要内容
临床试验/EUCTR2006-006166-42-DE
EUCTR2006-006166-42-DE进行中(未招募)不适用

Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie

niversity of Tuebingen0 个研究点开始时间: 2007年1月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Inclusion criteria for study participation are:
  • 1) definite diagnosis of PSP and dementia
  • 2) informed consent to study participation
  • 3) MMST > 18, therefore ability to give informed consent
  • 4) age over 50 years
  • 5) existence of a caregiver who can be suppervise the process of study medication
  • 6) ability to communicate verbally
  • 7) no other diseases affecting the central nervous system
  • 8) adequate capacity for study participation and steady state of health
  • 9) ability for consent is controlled by an independent physician
  • 10) written consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. history of addiction to alcohol or drugs
  • 2. signs of psychosis
  • 3. former history of ChEI medication
  • 4. pregnancy and breast feeding
  • 5. history of hypersensitivity aganst rivastigmine
  • 6. severe liver insufficiency
  • 7. history of sick-sinus-syndrom
  • 8. bronchial asthma or obstructiv lung desease
  • 9. activ gastric ulcer or duodenal ulcer
  • 10. history of retention of urine
  • 11. history of convulsion
  • anamnestisch erhobener Alkoholabusus
  • 2.akute Psychose
  • 3.Einnahme von Cholinesterasehemmern

研究者

发起方
niversity of Tuebingen

相似试验